obesity

News

Novo Nordisk shrugs off supply issues with record sales

Sales of Novo Nordisk’s fast-growing GLP-1 agonist drugs for diabetes and obesity may be held back by supply constraints, but feverish demand is still driving strong growt

News

Boehringer moves obesity therapy into phase 3

Boehringer Ingelheim and Zealand Pharma have kicked off three phase 3 trials of obesity drug candidate survodutide, in patients with and without diabetes, in the hope of b

R&D

GLP-1 weight loss drugs: An overview and update

GLP-1 agonists like Ozempic, Wegovy, and Mounjaro are dramatically changing the field of medically-assisted weight loss.

News

Wegovy finally reaches the UK, in 'limited' quantities

Novo Nordisk's sought-after obesity therapy Wegovy has finally reached the UK and can be prescribed by NHS weight management services – but supplies are being carefully co

News

Novo Nordisk buys another obesity biotech

Novo Nordisk has agreed its second acquisition in the space of a month of a biotech in the obesity category, snapping up fellow Danish company Embark Biotech for €15 milli

News